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Abstract
This short technical report describes the generation and characterization of a biolumines-
cence reporter mouse that is engineered to detect and longitudinally monitor the expression
of doxycycline-induced constitutively active β-catenin. The new responder transgenic
mouse contains the TetO-ΔN89β-CatTMILA transgene, which consists of the tet-operator fol-
lowed by a bicistronic sequence encoding a stabilized form of active β-catenin (ΔN89β-cate-
nin), an internal ribosome entry site, and the firefly luciferase gene. To confirm that the
transgene operates as designed, TetO-ΔN89β-CatTMILA transgenic mouse lines were
crossed with an effector mouse that harbors the mouse mammary tumor virus-reverse tetra-
cycline transactivator (MMTV-rtTA) transgene (termed MTB hereon), which primarily targets
rtTA expression to the mammary epithelium. Following doxycycline administration, the
resultant MTB/CatTMILA bigenic reporter exhibited precocious lobuloalveologenesis, ductal
hyperplasia, and mammary adenocarcinomas, which were visualized and monitored by in
vivo bioluminescence detection. Therefore, we predict that the TetO-ΔN89β-CatTMILA trans-
genic responder mouse—when crossed with the appropriate effector transgenic—will have
wide-applicability to non-invasively monitor the influence of constitutively active β-catenin
expression on cell-fate specification, proliferation, differentiation, and neoplastic transforma-
tion in a broad spectrum of target tissues.
Introduction
Apart from comprising stable cell adheren junctions, β-catenin is a critical effector of the Wnt
signaling pathway [1–3]. In Wnt’s absence, cytoplasmic β-catenin is normally targeted for ubi-
quitin-mediated proteolysis by glycogen synthase kinase-3β (GSK-3β) within a destruction-
complex with adenomatous polyposis coli (APC) and axin [4]. Specifically, GSK-3β phosphor-
ylates conserved N-terminal serine and threonine residues of β-catenin that post-translation-
ally mark β-catenin for destruction [5, 6]. In Wnt’s presence, GSK-3β is inactivated thereby
PLOS ONE | DOI:10.1371/journal.pone.0173014 March 2, 2017 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Szwarc MM, Kommagani R, Peavey MC,
Hai L, Lonard DM, Lydon JP (2017) A
bioluminescence reporter mouse that monitors
expression of constitutively active β-catenin. PLoS
ONE 12(3): e0173014. doi:10.1371/journal.
pone.0173014
Editor: Tiffany Seagroves, University of Tennessee
Health Science Center, UNITED STATES
Received: December 15, 2016
Accepted: February 13, 2017
Published: March 2, 2017
Copyright: © 2017 Szwarc et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This research was funded in part by: a
Cancer Prevention Research Institute of Texas pre-
doctoral fellowship grant (CPRIT: RP101499 (to
MMS)); a Baylor College of Medicine Reproductive
Endocrinology and Infertility Fellowship (to MCP); a
National Institutes of Health (NIH)/National Institute
of Child Health and Human Development (NICHD)
grant (K99 HD080742 (to RK)); a NIH/NICHD U01:
allowing β-catenin stabilization and nuclear translocation [7]. Within the nucleus, β-catenin
complexes with members of the T-cell factor/lymphoid enhancer factor (Tcf/Lef) family of
transcription factors that together control the expression of a myriad of target genes involved
in normal tissue development and function (http://www.stanford.edu/~rnusse/pathways/
targets.html).
Not surprisingly, aberrant β-catenin signaling is causal for numerous embryonic and post-
natal developmental abnormalities—including tumorigenesis—in diverse anatomic sites [1].
Mutations that prevent phosphorylation and turnover of the cytoplasmic pool of β-catenin
lead to the accumulation of a constitutively active form of β-catenin that can inappropriately
induce downstream Wnt target genes in a Wnt-independent manner. Importantly, the geneti-
cally engineered mouse was instrumental in validating many of the above findings in an in
vivo context.
Because the engineered mouse has been a pivotal in vivo experimental model to study Wnt
signaling in general and β-catenin signaling in particular, it is imperative that the full potential
of the mouse is attained to further advance our understanding of β-catenin action in vivo.
Accordingly, this brief technical report describes the generation and first-line characterization
studies of a new TetO-ΔN89β-CatTMILA transgenic mouse that enables noninvasive in vivo
detection of constitutively active β-catenin expression using a bioluminescence reporter.
Given the importance of β-catenin signaling in development, adult tissue homeostasis, and
tumorigenesis, we believe this bioluminescence reporter mouse will have wide-applicability.
Materials and methods
Creation of the TetO- ΔN89β-CatTMILA transgenic mouse
Mice were housed in an AAALAC accredited vivarium at Baylor College of Medicine, which
operates a 12h-light: 12h-dark recurrent photocycle in temperature-controlled mouse rooms
(22 ± 2˚C). Mice were fed irradiated Teklad global soy protein-free extruded rodent diet (Har-
lan Laboratories, Inc., Indianapolis, IN) and fresh water ad libitum when not treated with
doxycycline (see below). The TetO- ΔN89β-CatTMILA transgene was generated by inserting a
cDNA (2.1kb) encoding Xenopus ΔN89β-catenin [8–10] into unique EcoR1/Cla1 restriction
sites in the TMILA reporter vector (7.4kb (Chodosh plasmid #652)) [11]. The 89 amino acid
N-terminal deletion in ΔN89β-catenin renders the truncation mutant constitutively active [12,
13]. The insertion of the ΔN89β-catenin cDNA into the TMILA reporter vector positions the
ΔN89β-catenin cDNA downstream of the cytomegalovirus (CMV) minimal promoter and a
tandem repeat of seven Tet operator (TetO) sequences derived from the pTetSplice vector
[14]. With this cloning approach, the ΔN89β-catenin cDNA insertion is sequentially followed
by an internal ribosome entry site (IRES) and the codon optimized firefly luciferase 2 gene cas-
sette from Photinus pyralis (Promega, Madison, USA). A strong Simian virus 40 (SV40) splic-
ing/polyadenylation sequence is included at the 3’ end of the transgene. The resultant TetO-
ΔN89β-CatTMILA transgene (6.6kb) was released from pTetSplice vector sequences (2.9kb)
with Not1 digestion, isolated from vector sequences, and then purified for microinjection into
pronuclei of single-cell embryos of the FVB/N inbred strain. Founder mice (F0) and their
progeny were identified by PCR genotyping of genomic DNA isolated from tail snips. The
PCR primers that were used to detect the TetO- ΔN89β-CatTMILA transgene were previously
described [10]. Each of the four TetO- ΔN89β-CatTMILA responder transgenic lines (F1) was
crossed with the MTB effector transgenic [14] to generate MTB/CatTMILA bigenics that were
maintained in the FVB/N background strain. All studies described herein were conducted
with nulliparous mice that were hemizygous for the transgene.
A transgenic reporter mouse for β-catenin expression
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Ethics statement
All mouse studies were conducted in accordance with the Guide for the Care and Use of Labo-
ratory Animals published by the National Institutes of Health and animal protocols approved
by the Institutional Animal Care and Use Committee (IACUC) of Baylor College of Medicine
under protocol numbers AN-1513 and AN-544. Euthanasia was conducted by cervical disar-
ticulation while under surgical plane of anesthesia. CO2 euthanasia was conducted by use of
automated CO2 euthanasia chambers (Euthanex, Palmer, PA).
Transgene induction by doxycycline
Responder transgene expression in four-week-old MTB/CatTMILA bigenics was induced by
feeding rodent chow meal supplemented with doxycycline (6g/kg (BioServ, St. Louis, MO)).
Dispensed in light protected bottles, rodent water contained doxycycline (2mg/ml (BD Clon-
tech, San Diego, CA)) along with 5% sucrose to ameliorate taste aversion [10, 15, 16]. To main-
tain continued induction efficacy, doxycycline supplemented water was replaced every third
day.
Bioluminescence imaging
Twenty four hours prior to mouse imaging, the ventral area of the skin was depilated using a
commercially available depilating cream. On the day of imaging, isoflurane-anesthetized mice
were intraperitoneally injected with RediJect D-luciferin bioluminescent substrate (PerkinEl-
mer, Waltham, MA (150mg/kg)) in sterile 0.9% saline. After 5 minutes, bioluminescence was
detected and recorded using the Bruker FX Pro Imager (Bruker, Billerica, MA) equipped with
an isoflurane manifold for continuous anesthesia; mice were placed in the ventral recumbent
position for bioluminescence detection. Bioluminescence was captured within a 30 second
exposure time with 4x4 pixels binning followed by X-ray image capture (10 second exposure).
Using Bruker Molecular Imaging software (v.7.1.3.20550), bioluminescence images were
exported in pseudo color format with matched rainbow-colored bar scales (minimum and
maximum photons/second). For final presentation purposes, bioluminescence images were
overlaid upon the corresponding grey-scale X-ray image.
Whole mount, immunohistochemical, and western immunoblot analysis
Carmine-red stained mammary gland whole-mounts were performed as previously reported
[10, 15, 16]. The antibodies and conditions used for immunohistochemical detection of the
myc-epitope tag and 5’-bromo-2’-deoxyuridine (BrdU) incorporation have been described
[10]. To determine the percentage of mammary epithelial cells that is immunopositive for
Fig 1. Generation of the MTB/CatTMILA bigenic mouse. (A) Design of the TetO- ΔN89β-CatTMILA transgene. The ΔN89β-catenin
cDNA (2.1kb) was cloned into a single EcoR1 restriction site downstream of the TetO sequence in the TMILA (7.4kb) cloning vector
[11]. The ΔN89β-catenin cDNA encodes the truncated Xenopus β-catenin protein with a myc-epitope tag fused in-frame at its N-
terminus (black box). The location of the PCR primers for genotyping (black arrowheads) as well as the 13 centrally located Armadillo
repeats (Arm repeats) is indicated. The inserted ΔN89β-catenin cDNA is followed by an IRES and a cDNA encoding the firefly
luciferase protein. A SV40 polyadenylation signal (PA) serves as a strong transcriptional termination signal. The TetO- ΔN89β-
CatTMILA transgene was linearized with Not1, isolated from vector sequences, and purified prior to pronuclear microinjection. (B)
Schematic depicts the breeding strategy to generate the MTB/CatTMILA bigenic mice by crossing the MTB effector transgenic [14]
with TetO-ΔN89β-CatTMILA responder transgenic. (C) Typical western immunoblot of isolated mammary epithelial cell protein. Lane
1, 2, and 3 denote mammary epithelial protein isolated from wild type ((WT) or non-transgenic) control (without doxycycline), MTB/
CatTMILA bigenic (without doxycycline), and MTB/CatTMILA bigenic mice on food and water supplemented with doxycycline for
1-month respectively. Using antibodies to full-length β-catenin and the myc-epitope tag, the transgene-derived ΔN89β-catenin
protein (75kDa) is only detected in the MTB/CatTMILA bigenic treated with doxycycline (lane 3); β-actin serves as a loading control.
Each lane represents a protein isolate pooled from four individual mice per genotype and treatment.
doi:10.1371/journal.pone.0173014.g001
A transgenic reporter mouse for β-catenin expression
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BrdU incorporation, 6 control monogenic and 5 MTB/CatTMILA bigenics were used. Note:
ductal and alveolar epithelial cells were counted for the MTB/CatTMILA bigenic whereas only
ductal epithelial cells could be counted for the control monogenic gland since there are very
few alveolar cells in the adult virgin mammary epithelium to get an equivalent count. Only
intensely stained (dark brown) nuclei for BrdU incorporation were included in the cell count.
The average number of immunopositive cells was calculated from a total of 500 mammary
epithelial cells from three separate mammary gland sections per mouse. Final counts were
expressed as an average percentage mean of cells counted. Antibodies and conditions used
for western immunoblot detection of β-catenin, the myc-epitope tag, cyclin D1, and β-actin
in protein isolates from mammary epithelial cells and tumor tissue have been previously
detailed [10]. Mammary epithelial cell isolation was followed according to established methods
[17, 18].
Mammary tumor induction
Mice chronically administered doxycycline for mammary tumor induction were checked
twice weekly by manual palpation. Mice were euthanized when mammary tumors reached
approximately 1.0cm in diameter as measured by Vernier calipers. For each mouse, tumor
size, number, and ventral location were recorded prior to euthanasia. GraphPad Prism 6 soft-
ware (GraphPad Software, Inc., La Jolla, CA) was used to generate and statistically analyze
tumor-free Kaplan-Meier plot. The two-sided log-rank test was used to determine significance
of the difference in tumor-free rate between virgin bigenic mice that chronically received food
and water supplemented with doxycycline (n = 21) and bigenic mice maintained on regular
mouse chow (n = 28); a p-value <0.05 was considered significant.
Results and discussion
Design and generation of the TetO- ΔN89β-CatTMILA responder
transgenic mouse
The design of the TetO-ΔN89β-CatTMILA transgene is schematically shown in Fig 1A. The
Xenopus ΔN89β-catenin cDNA (2.1kb) was inserted between EcoR1 (5’) and Cla1 (3’) restric-
tion sites in the multiple cloning cassette of the TMILA vector (7.4kb) [11]. Note: the Xenopus
and human β-catenin protein sequences share 98% homology. To enable specific immunode-
tection, the ΔN89β-catenin cDNA was engineered to express in-frame a myc-epitope tag at the
N-terminus of the ΔN89β-catenin protein [10]. Due to deletion of its first 89 amino acids, the
ΔN89β-catenin protein is constitutively active. The insertion of the ΔN89β-catenin cDNA into
Fig 2. Doxycycline-induced bioluminescence in the mammary gland of the MTB/CatTMILA bigenic. (A) Overlay of full-body bioluminescence and
x-ray images of monogenic control (G6719 (ear tag#)) and MTB/CatTMILA bigenic (G6718 (ear tag#)) mice following 0, 24, and 48 hours of doxycycline
intake. By 24 hours of doxycycline administration, bioluminescence activity is detected in the #2, #3 (thoracic), and #4 (inguinal) mammary glands of the
MTB/CatTMILA bigenic (G6718) but not in the monogenic control mouse (G6719). (B) Whole mount of mammary gland from monogenic control mouse
(G6719) shows normal ductal morphogenesis (black arrowhead) following 1-week of doxycycline administration. (C) Mammary gland whole mount
analysis shows precocious lobuloalveologenesis (white arrowhead) in the similarly treated MTB/CatTMILA bigenic (G6718). Scale bar in (B) applies to
(C); see S1 Fig for corresponding low magnification images. (D) Myc-epitope tag immunohistochemistry does not detect myc-epitope taggedΔN89β-
catenin expression in the mammary epithelium of the doxycycline treated monogenic (G6719) control (black arrowhead). (E) Myc-tagged ΔN89β-
catenin expression is clearly detected in the mammary epithelium of the similarly treated MTB/CatTMILA bigenic (white arrowhead); (F) is a higher
magnification of (E). (G) Image shows a representative transverse section of an epithelial duct in the mammary gland of the doxycycline-treated
monogenic (G6719) control mouse, which scores negative for BrdU incorporation following BrdU immunohistochemistry (black arrowhead). (H)
Numerous cells scoring positive for BrdU incorporation are detected in the mammary epithelium of the similarly treated MTB/CatTMILA bigenic (white
arrowhead); (I) is a higher magnification. Scale bar in (D) and (F) apply to (E, G, and H) and (I) respectively. See S1 Fig for more details and quantitation
of BrdU positive cells in the mammary epithelium of both genotypes following doxycycline administration.
doi:10.1371/journal.pone.0173014.g002
A transgenic reporter mouse for β-catenin expression
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Fig 3. Bioluminescence detection of the emergence of doxycycline-induced mammary tumors in the MTB/CatTMILA bigenic. (A)
Overlay of whole-body bioluminescence and X-ray images shows mammary tumor enlargement in the MTB/CatTMILA bigenic (G6687)
following doxycycline administration for the time periods indicated. Note the emergence of a thoracic mammary tumor (white arrowhead) in
the bigenic. As expected, luciferase activity is not detected in the similarly treated monogenic control (G6688). Corresponding whole-body
X-rays are shown alone in the bottom panels to enable clear visualization of the mammary tumor mass (white arrow head). (B) The MTB/
CatTMILA bigenic (G6687) is shown following bioluminescence monitoring; note the thoracic mammary tumor detected in (A) above (white
A transgenic reporter mouse for β-catenin expression
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the TMILA vector positions the cDNA downstream of the Tet operator (TetO) sequences and
upstream of (in sequential order) the IRES, luciferase reporter, and the SV40 intron/polyA
cassette. With standard transgenic methodology [10, 15, 16, 19], four out of six mice positive
for the TetO- ΔN89β-CatTMILA transgene transmitted the transgene through the germline
(#G4704; #G4715; #G4717; and #G4720). To confirm that ΔN89β-catenin is expressed by
these transgenics in response to doxycycline administration, each of the four transgenic lines
was crossed with the MTB effector transgenic [14] to generate the MTB/CatTMILA bigenic (Fig
1B). Unless otherwise stated, data derived from the #G4715 are shown herein which are re-
presentative of the other transgenic lines. Western immunodetection for β-catenin and the
myc-epitope tag demonstrates that the transgene-derived ΔN89β-catenin protein (75kDa) is
specifically expressed in mammary epithelial protein isolates derived from the MTB/CatTMILA
bigenic in response to doxycycline administration (Fig 1C).
Doxycycline induction of ΔN89β-catenin expression in the mammary
epithelium of the virgin MTB/CatTMILA bigenic is detected by
bioluminescence
Using the luciferase reporter as a surrogate for transgene-derived ΔN89β-catenin expression,
the bioluminescence emission signal was detected as early as 24 hours following doxycycline
administration in the MTB/CatTMILA bigenic (Fig 2A). The bioluminescence signal was
detected in the majority of mammary glands (thoracic and inguinal) in the adult virgin MTB/
CatTMILA bigenic; as expected, the bioluminescence signal was not detected in the control
mouse (Fig 2A). Within a short time-period, only the mammary gland of the doxycycline-
treated MTB/CatTMILA bigenic exhibited precocious lobuloalveologenesis and ductal side-
branching (Fig 2B and 2C). This result demonstrates that the TetO-ΔN89β-CatTMILA
responder transgene both operates as a bioluminescent reporter and causes β-catenin-depen-
dent disruption of epithelial growth homeostasis. Immunohistochemical staining for the myc-
epitope tag and BrdU incorporation demonstrated that ΔN89β-catenin expression was
restricted to the nucleus and cytoplasm of the mammary epithelium and that this expression
pattern was coincident with mammary epithelial hyperplasia (Fig 2D–2I). Collectively, these
data show that bioluminescence detection can forecast ΔN89β-catenin induced mammary epi-
thelial abnormalities in the MTB/CatTMILA bigenic reporter mouse.
Longitudinal monitoring of mammary tumor progression in the MTB/
CatTMILA bigenic reporter mouse
With continuous doxycycline administration, the MTB/CatTMILA bigenic reporter mouse
develops palpable mammary tumors that can be detected and longitudinally monitored by bio-
luminescence (Fig 3A). As expected these mammary tumors are mostly adenocarcinomas that
exhibit a strong immunopositive signal for the transgene-derived myc-epitope tag and are
highly proliferative (Fig 3B–3F). The mammary tumor phenotype is 100% penetrant and is
completely dependent on doxycycline administration (Fig 4A); many of the MTB/CatTMILA
bigenic reporters exhibit multifocal mammary tumors that are readily visualized by biolumi-
nescence detection (Fig 4B and 4C). Although most of the MTB/CatTMILA mammary tumors
are adenocarcinomas (Fig 3B–3F), approximately 15% of tumors are squamous metaplasias
arrowhead). (C) and (D) are low and high magnification images respectively of mammary tumor tissue sections immunostained for myc-
tagged ΔN89β-catenin expression; note: that most tumor cells score positive for myc-tag immunoreactivity (white arrowhead). (E) and (F)
are low and high magnification images of mammary tumor tissue sections stained for BrdU incorporation; many tumor cells are
immunopositive for BrdU incorporation (white arrowhead). Scale bar in (C) and (D) applies to (E) and (F) respectively.
doi:10.1371/journal.pone.0173014.g003
A transgenic reporter mouse for β-catenin expression
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[20, 21] that are strongly immunopositive for the transgene-derived myc-epitope tag and
BrdU incorporation (Fig 4D–4G). Interestingly, approximately 10% of MTB/CatTMILA palpa-
ble mammary tumors do not regress following doxycycline withdrawal (S2A Fig). Biolumines-
cence monitoring clearly reveals that transgene expression activity is rapidly attenuated
following doxycycline withdrawal but mammary tumor volume does not decrease (S2A and
S2B Fig). These findings are confirmed by western blot and immunohistochemical analysis
which show absence of ΔN89β-catenin protein in mammary tumors that continue to expand
despite the absence of doxycycline exposure (S2C and S2D Fig). For the majority of mice, how-
ever, mammary tumors regress within 2-weeks following doxycycline withdrawal (S3 Fig).
Doxycycline-induction of ΔN89β-catenin expression in the murine salivary
gland can be temporally monitored using bioluminescence detection
Bioluminescence monitoring also reveals that progeny from one transgenic line (#G4704)
exhibit particularly strong ΔN89β-catenin expression in the submandibular salivary gland with
low expression in the mammary epithelium (Fig 5A). Following chronic doxycycline exposure,
histological analysis of all bigenic mice from this transgenic line revealed that the salivary
gland exhibited epithelial hyperplasia that was strongly positive for myc-epitope tag expression
(Fig 5B–5G). This result is not surprising as the MTB effector mouse has been shown to
express rtTA activity in the salivary gland [14], an exocrine tissue developmentally similar to
the mammary gland. However, we did not observe strong transgene expression in both the sal-
ivary and mammary gland in any transgenics examined. Because dysregulation of β-catenin
signaling has been shown to elicit salivary gland tumorigenesis [22–24], this model may be
useful as a non-invasive tool to explore further the involvement of β-catenin signaling in the
ontogenesis of this poorly understood head and neck cancer.
Conclusion
We and others previously generated variations of the TetO- ΔN89β-Catenin transgenic effec-
tor mouse that was designed to conditionally induce constitutively activated ΔN89β-catenin
protein in response to doxycycline [10, 25]. In this short technical report, we describe an
important improvement to this model with the generation of the TetO- ΔN89β-CatTMILA
transgenic, which has the added capability of bioluminescence detection. Because of the obvi-
ous advantages of optical bioluminescence imaging—a rapid, sensitive, and user-friendly opti-
cal modality for temporal assessment of tumor progression and therapy—along with the
pleiotropic role of β-catenin signaling in normal and abnormal tissue homeostasis, we antici-
pate that this new bioluminescence reporter mouse will prove to be invaluable for future inves-
tigations to discern the normal and pathogenic role of β-catenin in vivo.
Fig 4. Complete penetrance of the mammary tumor phenotype in the MTB/CatTMILA bigenic reporter.
(A) Kaplan-Meier tumor free plot for MTB/CatTMILA bigenics without doxycycline administration (n = 28 (blue))
and doxycycline-treated MTB/CatTMILA bigenics (n = 21 (red)) showing percent tumor free on the Y-axis
versus age (in days) on the X-axis. (B) Overlay of whole-body bioluminescence and x-ray images of a MTB/
CatTMILA (G6274) bigenic revealing two ipsilateral mammary gland tumors (#2 and #3 thoracic mammary
glands (white arrowheads)). (C) The MTB/CatTMILA (G6274) bigenic reporter exhibiting two mammary tumors
shown in (B (white arrowheads)). (D) Hematoxylin and eosin staining reveals that a subset of MTB/CatTMILA
mammary tumors exhibit histologic characteristics consistent with squamous differentiation as evidence by
the presence of pilar-like structures of confluent swirls of laminar keratin [20, 21]; (E) higher magnification of
image shown in (D). (F) Typical immunostaining for myc-tagged ΔN89β-catenin expression in these tumors
(white arrowhead). (G) Representative staining for BrdU incorporation in these tumors. Note that BrdU
positive cells are localized to the region of the tumor that expresses ΔN89β-catenin (compare F with G (white
arrowheads)); scale bar in (D) and (E) corresponds to (F) and (G) respectively.
doi:10.1371/journal.pone.0173014.g004
A transgenic reporter mouse for β-catenin expression
PLOS ONE | DOI:10.1371/journal.pone.0173014 March 2, 2017 10 / 15
Fig 5. Bioluminescence monitoring of doxycycline-inducedΔN89β-catenin expression in the salivary gland of the MTB/CatTMILA bigenic. (A)
Overlay of whole body bioluminescence and X-ray images of MTB/CatTMILA bigenic mouse following doxycycline administration for the indicated time
periods. Note the localization of the bioluminescence signal to the submandibular salivary gland of the MTB/CatTMILA mouse (G8335). (B-D) and (E-G)
panels represent salivary gland tissue immunostained for the transgene-derived myc-tagged ΔN89β-catenin protein and BrdU incorporation
respectively. (B) Salivary gland tissue from doxycycline-treated monogenic control does not score positive for myc-tagged ΔN89β-catenin expression.
(C) Cystic hyperplasia with strong immunostaining for myc-tagged ΔN89β-catenin expression is evident in salivary gland tissue isolated from the MTB/
CatTMILA bigenic following 336 hours of doxycycline administration (black arrowhead). (D) is a higher magnification image of (C). (E) Salivary gland
epithelial cells positive for BrdU are not evident in salivary gland tissue derived from doxycycline-treated monogenic control mice (black arrowhead). (F)
Many cells score positive for BrdU incorporation in salivary gland tissue isolated from the similarly treated MTB/CatTMILA bigenic (black arrowhead); a
higher magnification is shown in (G (black arrowhead)). Note: To date, we have not detected palable salivary tumors in these mice. Scale bar in (B) and
(D) apply to (C, E, and F) and (G) respectively.
doi:10.1371/journal.pone.0173014.g005
A transgenic reporter mouse for β-catenin expression
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Supporting information
S1 Fig. Doxycycline-induction of precocious lobuloalveologenesis in the mammary gland
of the MTB/CatTMILA reporter mouse. (A) and (B) represent low magnification whole mount
images of mammary gland tissue isolated from a monogenic control (G6719) and a MTB/CatT-
MILA bigenic (G6718) respectively following doxycycline administration for 1-week (see Fig 2).
Scale bar in (A) applies to (B); LN denotes lymph node in inguinal mammary gland. At
increasing magnification, (C-E) show a typical transverse section of a doxycycline-treated con-
trol monogenic mammary duct with a single luminal epithelial cell scoring positive for BrdU
incorporation (white arrowhead). At increasing magnification, (F-H) show numerous alveolar
epithelial cells in the doxycycline-treated MTB/CatTMILA bigenic mammary gland that are
immunopositive for BrdU incorporation (white arrowhead). As a positive control for BrdU
immunostaining, (I) shows BrdU positive cells in the lymph node of inguinal (#4) mammary
gland of the doxycycline-treated monogenic control (white arrowhead). (J) shows the exten-
sive alveologenesis and cellular proliferation (white arrowhead) that occurs in the doxycycline-
treated MTB/CatTMILA bigenic mammary gland. Scale bar in (C-E) applies to (F-H) respec-
tively; scale bar in (E) also applies to (I-J). (K) displays a histogram of the mean percentage of
cells (± s.e.m.) scoring positive for BrdU incorporation in ductal epithelium of the doxycy-
cline-treated control monogenic (n = 6) and in the ductal and alveolar epithelium of the doxy-
cycline-treated MTB/CatTMILA bigenic sibling (n = 5); denotes P value <0.0001.
(TIF)
S2 Fig. Subset of MTB/CatTMILA mammary gland tumors do not regress following doxycy-
cline removal. (A) Overlay of whole body bioluminescence and x-ray images of monogenic
control (G6101) and MTB/CatTMILA (G6100) bigenic following removal of doxycycline for the
time period indicated. By 120 hours post doxycycline removal, transgene-derived luciferase
activity is significantly attenuated but mammary tumor mass is not reduced (white arrow-
head). (B) Top two panels (low and high magnification) show MTB/CatTMILA (G6100) bigenic
at 0h after doxycycline withdrawal; white arrowhead points to thoracic mammary gland tumor
shown in (A). Two bottom panels (low and high magnification) show the MTB/CatTMILA
(G6100) bigenic 144 hours following doxycycline withdrawal. Note that the mammary tumor
has not decreased in size following de-induction of the transgene (white arrowhead). (C)
Western immunoblot of protein isolated from: WT mammary epithelial cells (lane 1), three
separate MTB/CatTMILA bigenic mammary tumors on doxycycline (lanes 2–4), and MTB/
CatTMILA bigenic mammary tumor off doxycycline for 144 days (lane 5). Note the absence of
transgene-derived ΔN89β-catenin protein in lane 5. High levels of cyclin D1 protein expres-
sion is detected in all mammary tumor samples (lanes 2–5); β-actin serves as a loading control.
(D) Immunohistochemistry does not detect transgene-derived myc-tagged ΔN89β-catenin in
mammary tumor tissue (adenocarcinoma) derived from MTB/CatTMILA bigenic that are off
doxycycline for 144 hours. The same mammary tumor tissue is highly proliferative as evi-
denced by numerous tumor cells scoring positive for BrdU incorporation (white arrowhead).
Scale bar applies to both panels.
(TIF)
S3 Fig. The majority of palpable mammary tumors in the MTB/CatTMILA bigenic that are
induced by doxycycline fully regress by 14 days following doxycycline withdrawal. A rep-
resentative MTB/CatTMILA bigenic with a palpable mammary tumor is shown (black arrow-
head) in the top two panels (low and high magnification). For this representative mouse, 136
days of doxycycline administration was required to induce a palpable thoracic (#3) mammary
tumor with a ~1cm diameter. Following 6-days on a standard diet without doxycycline (or
A transgenic reporter mouse for β-catenin expression
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de-induction), the size of the same tumor rapidly reduced (middle two panels). By 12-days
without doxycycline in the diet, the thoracic mammary tumor in the MTB/CatTMILA bigenic
is undetectable by manual palpation. Of the MTB/CatTMILA bigenic mice in this study
(n = 20), 18 mice showed rapid mammary tumor regression within 14-days whereas 2 mice
did not show mammary tumor regression within this time period (S2 Fig).
(TIF)
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